Gerald Raverot


Affiliation: Hospices Civils de Lyon
Country: France


  1. Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G. Pathological markers of somatotroph pituitary neuroendocrine tumors (PitNET)s predicting the response to medical treatment. Minerva Endocrinol. 2018;: pubmed publisher
    ..Such pathological profiling could become a useful decision-making tool for clinicians in the context of a multidisciplinary approach, after surgery failure. ..
  2. Lasolle H, Vasiljevic A, Borson Chazot F, Raverot G. Pasireotide: A potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris). 2018;: pubmed publisher
    ..Pasireotide could thus be an alternative in prolactinomas resistant to DA. SSTR expression analysis on pathology could guide patient selection. ..
  3. Raverot G, Assié G, Cotton F, Cogne M, Boulin A, Dherbomez M, et al. Biological and radiological exploration and management of non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76:201-9 pubmed publisher
    ..We also drew up basic rules for initial exploration and radiological follow-up of both operated and non-operated pituitary adenomas. ..
  4. Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, et al. Aggressive pituitary tumours and carcinomas: two sides of the same coin?. Eur J Endocrinol. 2018;178:C7-C9 pubmed publisher
    ..Whilst the survey focused on treatment effectiveness, all pathological data were not explored in detail. Here, we comment on some interesting pathological findings, notably the difference between APT and PC. ..
  5. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson Chazot F, Lachuer J, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol. 2010;163:35-43 pubmed publisher
    ..65; P<0.05). Despite the absence of hypercortisolism, SCAs exhibit histological, biochemical and molecular corticotroph differentiation. SCA and MCA show hormonal and molecular similarities differentiating them from mCA. ..
  6. Chanal M, Chevallier P, Raverot V, Fonteneau G, Lucia K, Monteserin Garcia J, et al. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. Mol Cancer Ther. 2016;15:1261-70 pubmed publisher
    ..Altogether, these results show a potential for PI3K inhibitors in the management of aggressive pituitary tumors. Mol Cancer Ther; 15(6); 1261-70. ©2016 AACR. ..
  7. Lasolle H, Raverot G. Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. Presse Med. 2016;45:e211-6 pubmed publisher
    ..Here, we review results of temozolomide treatment in this indication and discuss the interest of different prognostic markers and perspectives for new therapeutics. ..
  8. request reprint
    Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol. 2017;176:195-201 pubmed
    ..A low secretory activity of these tumours might explain the normal plasma values for GH and insulin-like growth factor 1 (IGF1) and the absence of clinical signs of acromegaly. ..
  9. Raverot G, Vasiljevic A, Jouanneau E. Prognostic factors of regrowth in nonfunctioning pituitary tumors. Pituitary. 2018;21:176-182 pubmed publisher
    ..Recent advances in pathological classification may be the first step for identification of NFPTs with a high risk of recurrence. ..

More Information


  1. Nouvel M, Rabilloud M, Raverot V, Subtil F, Vouillarmet J, Thivolet C, et al. Performance of the 4-mg intravenous dexamethasone suppression test in differentiating Cushing disease from pseudo-Cushing syndrome. Ann Endocrinol (Paris). 2016;77:30-6 pubmed publisher
    ..3% [67-94]. The 4-mg IV DST is an easy and accurate tool in distinguishing CD from PCS. It deserves thus a better place in establishing the diagnosis of CD. ..
  2. request reprint
    Vasiljevic A, Jouanneau E, Trouillas J, Raverot G. Clinicopathological prognostic and theranostic markers in pituitary tumors. Minerva Endocrinol. 2016;41:377-89 pubmed
    ..Analysis of theranostic factors such as O6-methylguanine-DNA methyl-transferase or somatostatin receptor expression may guide the choice of postoperative treatment. ..
  3. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95:4592-9 pubmed publisher
    ..Increased expression of O6-methylguanine-DNA-methyltranferase (MGMT) has been suggested to predict resistance to temozolomide...
  4. Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, et al. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol. 2017;176:769-777 pubmed publisher
    ..Patients in our series showed a 51.2% response rate to TMZ, with an improved survival among responders despite frequent relapses. Our study highlights the high variability and lack of standardization of treatment protocols. ..
  5. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2017;: pubmed publisher
    ..The present ESE guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas...